Welcome!

News Feed Item

Acura Pharmaceuticals Announces Fourth Quarter and Full Year 2013 Financial Results

PALATINE, IL -- (Marketwired) -- 03/03/14 -- Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the year and three months ended December 31, 2013.

The Company reported a net loss of $3.4 million for the fourth quarter 2013 or $0.07 per diluted share, compared to net loss of $3.0 million or $0.06 per diluted share for the same period in 2012.

Research and development expenses associated with product candidates utilizing the Company's AVERSION® and IMPEDE® Technologies were $0.8 million in the fourth quarter 2013, compared to $1.2 million for the same period in 2012. Selling, marketing, general and administrative expenses were $2.8 million in the fourth quarter 2013, versus $1.8 million in the same period last year. Selling and marketing expenses for the three months ended December 31, 2013 primarily consisted of advertising and marketing activities for NEXAFED®.

For the twelve months ended December 31, 2013, Acura recorded $0.1 million in revenues compared with no revenue in the same period in 2012. These revenues were derived from the Company's sale of NEXAFED and royalties from our licensing partner on sales of Oxecta®. In the fourth quarter of 2013, the Company shipped $0.3 million of NEXAFED but because certain customers have a right of return, the Company recognized only a portion of these sales while establishing a reserve against any future potential product returns. In future periods, as the right of return no longer exists or returns can be reliably estimated, the Company will adjust this reserve.

Research and development expenses were $4.9 million in the twelve months ended December 31, 2013, compared to $3.7 million in the same period in 2012. Selling, marketing, general and administrative expenses were $8.9 million in the twelve months ended December 31, 2013, versus $6.0 million in the same period last year. The Company reported a net loss of $13.9 million or $0.29 per diluted share, for the twelve months ending December 31, 2013, compared to a net loss of $9.7 million or $0.20 per diluted share for the same period in 2012.At December 31, 2013 the Company had cash, cash equivalents and marketable securities totaling $26.1 million. During year the Company raised capital of $3.2 million from the sale of common stock on the open market and $10.0 million in term debt financing.

Conference Call Information
Acura Pharmaceuticals, Inc. will host a conference call on Tuesday, March 4, 2014 at 8:30 a.m. ET to discuss the results.

To participate in the live conference call, please dial 888-539-3612 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 8601696.

A replay of the call will be available beginning March 5, 2014 at 11:30 a.m. ET and ending on March 25, 2014 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 8601696.

About Acura Pharmaceuticals
Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION® and IMPEDE® Technologies. AVERSION® contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages. IMPEDE® is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXECTA® (oxycodone HC1 tablets) which incorporates the AVERSION® technology. The Company has a development pipeline of additional AVERSION® technology products containing other opioids.

The trademark OXECTA® is owned by Pfizer Inc.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Forward-looking statements may include, but are not limited to, our and our licensee's ability to successfully launch and commercialize our products and technologies including OXECTA® Tablets and NEXAFED® Tablets, the price discounting that may be offered by Pfizer for OXECTA®, our and our licensee's ability to obtain necessary regulatory approvals and commercialize products utilizing our technologies and the market acceptance of and competitive environment for any of our products, the willingness of wholesalers and pharmacies to stock NEXAFED® Tablets, expectations regarding potential market share for our products and the timing of first sales, our ability to enter into additional license agreements for our AVERSION® Technology product candidates, our exposure to product liability and other lawsuits in connection with the commercialization of our products, the increasing cost of insurance and the availability of product liability insurance coverage, the ability to avoid infringement of patents, trademarks and other proprietary rights of third parties, and the ability of our patents to protect our products from generic competition, our ability to protect and enforce our patent rights in any paragraph IV patent infringement litigation, and the ability to fulfill the FDA requirements for approving our product candidates for commercial manufacturing and distribution in the United States, including, without limitation, the adequacy of the results of the laboratory and clinical studies completed to date, the results of laboratory and clinical studies we may complete in the future to support FDA approval of our product candidates and the sufficiency of our development to meet OTC Monograph standards as applicable, the adequacy of the development program for our product candidates, including whether additional clinical studies will be required to support FDA approval of our product candidates, changes in regulatory requirements, adverse safety findings relating to our product candidates, whether the FDA will agree with our analysis of our clinical and laboratory studies and how it may evaluate the results of these studies or whether further studies of our product candidates will be required to support FDA approval, whether or when we are able to obtain FDA approval of labeling for our product candidates for the proposed indications and will be able to promote the features of our abuse discouraging technologies, whether our product candidates will ultimately deter abuse in commercial settings and whether our IMPEDE technology will disrupt the processing of pseudoephedrine into methamphetamine. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "indicates," "estimates," "projects," "predicts," "potential" and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission.

                         ACURA PHARMACEUTICALS, INC.
                    CONDENSED CONSOLIDATED BALANCE SHEETS
                               (in thousands)

                                                    (audited)     (audited)
                                                  December 31,  December 31,
                                                      2013          2012
----------------------------------------------------------------------------
Current assets                                    $     27,453  $     27,996
Property, plant and equipment, net                         941         1,052
Other assets                                               236            11
----------------------------------------------------------------------------
  Total assets                                    $     28,630  $     29,059
----------------------------------------------------------------------------

Current liabilities                               $        820  $      1,424
Deferred revenue                                           287             -
Long-term debt, net of $400 of debt discount             9,600             -
Other liabilities                                            -             5
Stockholders' equity                                    17,923        27,630
----------------------------------------------------------------------------
  Total liabilities and stockholders' equity      $     28,630  $     29,059
----------------------------------------------------------------------------


                        ACURA PHARMACEUTICALS, INC.
           CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
                   (in thousands, except per share data)

                                       (audited)            (unaudited)
                                  Twelve Months Ended   Three Months Ended
                                     December 31,          December 31,
                                    2013       2012       2013       2012
----------------------------------------------------------------------------
Revenues:
  Royalty revenue                $      10  $       -  $       2  $       -
  Product sales, net                   113          -         33          -
----------------------------------------------------------------------------
      Total revenues, net              123          -         35          -
----------------------------------------------------------------------------
Operating expenses:
  Cost of sales (excluding
   write-down)                         114          -         36          -
  Inventory write-down (write-
   up)                                 250          -       (111)         -
  Research and development           4,923      3,726        803      1,208
  Selling, marketing, general
   and administrative                8,926      6,013      2,788      1,849
----------------------------------------------------------------------------
      Total operating expenses      14,213      9,739      3,516      3,057
----------------------------------------------------------------------------
      Operating loss               (14,090)    (9,739)    (3,481)    (3,057)
Non-operating income (expense):
  Investment income                    194         79         58         48
  Gain (loss) on sales of
   marketable securities                 4          -         15          -
  Other expense, net                    (9)        (8)        (9)        (7)
----------------------------------------------------------------------------
      Total other income
       (expense), net                  189         71         64         41
----------------------------------------------------------------------------
      Loss before income taxes     (13,901)    (9,668)    (3,417)    (3,016)
  Provision for income taxes             -          -          -          -
----------------------------------------------------------------------------
      Net loss                   $ (13,901) $  (9,668) $  (3,417) $  (3,016)
----------------------------------------------------------------------------
Other comprehensive income
 (loss), net of tax:
  Unrealized gains (losses) on
   securities                           59        (40)        24        (40)
----------------------------------------------------------------------------
      Total other comprehensive
       income (loss)                    59        (40)        24        (40)
----------------------------------------------------------------------------
      Comprehensive income
       (loss)                    $ (13,842) $  (9,708) $  (3,393) $  (3,056)
----------------------------------------------------------------------------


----------------------------------------------------------------------------
Loss per share:
    Basic                        $   (0.29) $   (0.20) $   (0.07) $   (0.06)
    Diluted                      $   (0.29) $   (0.20) $   (0.07) $   (0.06)
----------------------------------------------------------------------------
Weighted average shares
 outstanding:
    Basic                           47,764     47,521     49,152     47,523
    Diluted                         47,764     47,521     49,152     47,523
----------------------------------------------------------------------------

Contact:
for Acura Investor Relations
Email Contact
847-705-7709

for Acura Media Relations
Email Contact
847-705-7709

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
You want to start your DevOps journey but where do you begin? Do you say DevOps loudly 5 times while looking in the mirror and it suddenly appears? Do you hire someone? Do you upskill your existing team? Here are some tips to help support your DevOps transformation. Conor Delanbanque has been involved with building & scaling teams in the DevOps space globally. He is the Head of DevOps Practice at MThree Consulting, a global technology consultancy. Conor founded the Future of DevOps Thought Leade...
Everyone wants the rainbow - reduced IT costs, scalability, continuity, flexibility, manageability, and innovation. But in order to get to that collaboration rainbow, you need the cloud! In this presentation, we'll cover three areas: First - the rainbow of benefits from cloud collaboration. There are many different reasons why more and more companies and institutions are moving to the cloud. Benefits include: cost savings (reducing on-prem infrastructure, reducing data center foot print, redu...
Founded in 2000, Chetu Inc. is a global provider of customized software development solutions and IT staff augmentation services for software technology providers. By providing clients with unparalleled niche technology expertise and industry experience, Chetu has become the premiere long-term, back-end software development partner for start-ups, SMBs, and Fortune 500 companies. Chetu is headquartered in Plantation, Florida, with thirteen offices throughout the U.S. and abroad.
René Bostic is the Technical VP of the IBM Cloud Unit in North America. Enjoying her career with IBM during the modern millennial technological era, she is an expert in cloud computing, DevOps and emerging cloud technologies such as Blockchain. Her strengths and core competencies include a proven record of accomplishments in consensus building at all levels to assess, plan, and implement enterprise and cloud computing solutions. René is a member of the Society of Women Engineers (SWE) and a m...
In his session at 20th Cloud Expo, Mike Johnston, an infrastructure engineer at Supergiant.io, discussed how to use Kubernetes to set up a SaaS infrastructure for your business. Mike Johnston is an infrastructure engineer at Supergiant.io with over 12 years of experience designing, deploying, and maintaining server and workstation infrastructure at all scales. He has experience with brick and mortar data centers as well as cloud providers like Digital Ocean, Amazon Web Services, and Rackspace. H...
The technologies behind big data and cloud computing are converging quickly, offering businesses new capabilities for fast, easy, wide-ranging access to data. However, to capitalize on the cost-efficiencies and time-to-value opportunities of analytics in the cloud, big data and cloud technologies must be integrated and managed properly. Pythian's Director of Big Data and Data Science, Danil Zburivsky will explore: The main technology components and best practices being deployed to take advantage...
SYS-CON Events announced today that DatacenterDynamics has been named “Media Sponsor” of SYS-CON's 18th International Cloud Expo, which will take place on June 7–9, 2016, at the Javits Center in New York City, NY. DatacenterDynamics is a brand of DCD Group, a global B2B media and publishing company that develops products to help senior professionals in the world's most ICT dependent organizations make risk-based infrastructure and capacity decisions.
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
"When you think about the data center today, there's constant evolution, The evolution of the data center and the needs of the consumer of technology change, and they change constantly," stated Matt Kalmenson, VP of Sales, Service and Cloud Providers at Veeam Software, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Today, we have more data to manage than ever. We also have better algorithms that help us access our data faster. Cloud is the driving force behind many of the data warehouse advancements we have enjoyed in recent years. But what are the best practices for storing data in the cloud for machine learning and data science applications?
Andi Mann, Chief Technology Advocate at Splunk, is an accomplished digital business executive with extensive global expertise as a strategist, technologist, innovator, marketer, and communicator. For over 30 years across five continents, he has built success with Fortune 500 corporations, vendors, governments, and as a leading research analyst and consultant.
A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to great conferences, helping you discover new conferences and increase your return on investment.
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER gives detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPOalso offers sp...